Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Braxia Scientific Corp C.BRAX

Alternate Symbol(s):  BRAXF

Braxia Scientific Corp. is a Canada-based medical research and telemedicine company with a clinic that provide ketamine treatments for persons with depression and related disorders. Through its medical solutions, it intends to reduce the illness burden of brain-based disorders, such as major depressive disorder, among others. The Company is primarily focused on owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and research activities related to discovering and commercializing novel drugs and delivery methods. It seeks to develop ketamine and derivatives and other psychedelic products from its IP development platform. The Company has clinic operations in the Canadian cities of Mississauga, Kitchener-Waterloo, Ottawa and Montreal. Its subsidiary, Braxia Health, is engaged in offering rapid onset treatments to aid those suffering from several treatment-resistant conditions, such as depression and bipolar disorder.


CSE:BRAX - Post by User

Comment by yf4l8888on Feb 17, 2021 7:58pm
168 Views
Post# 32591923

RE:RE:They HAVE NOT filed the new papers yet.

RE:RE:They HAVE NOT filed the new papers yet.

Not going to repost the NR because most have probably read and it's quite long, however, it is correct the FINAL versions have not been filed.  However, it does state several times through out the release DRAFTS of the filings have been submitted to the Commission for review.  I'm sure most people realize this is standard process so any additional questions/comments can be addressed.  That is VERY different from saying they have not filed anything at all.

To be clear also, this is not a defense or attack on the status of the company, people involved...etc. Simply to clarify what has or has not been submitted.

"The Company has submitted drafts of the restated condensed interim consolidated financial statements and management's discussion & analysis ("MD&A") for the three and six month periods ended March 31, 2020 (the "Restated Financial Statements and MD&A") and the September Financial Statements and MD&A to the Commission for review. Until the Restated Financial Statements and MD&A are filed, the Original Financial Statements and MD&A should not be relied upon and should be considered to have been withdrawn.

CSE Listing Status/Cease Trade Orders

The Company has also today filed a draft of a new Listing Statement with the Commission and the Canadian Securities Exchange ("CSE") for review. The Listing Statement reflects the acquisition of Altmed and the RTO. The Company was required to file the new Listing Statement as a condition to the lifting of the existing cease trade orders issued by the Commission and prior to the Company's Common Shares being reinstated for trading on the CSE. The existing cease trade orders, issued on August 26, 2020 and October 27, 2020, effectively provide that the Company must file:

 

  • a revised material change report reflecting the accounting treatment for the Altmed transaction
  • interim financial statements for the period ended June 30, 2020,
  • interim MD&A to June 30, 2020, and
  • certification of interim filings for the period ended June 30,2020.

 

Drafts of these filings have been submitted to the Commission for review. The Company is working diligently with the Commission and the CSE to ensure that the revocation of the existing cease trade orders against the Company and the filing of the new Listing Statement occur as soon as possible. However, there can be no assurance as to when (if ever) the Restated Financial Statements and MD&A and the September Financial Statements and MD&A will be filed. Similarly, there can be no assurance as to when (if ever) the existing cease trade orders will be lifted, the new Listing Statement will be completed and trading in the Company's Common Shares will be reinstated on the CSE."

<< Previous
Bullboard Posts
Next >>